SC
COGT icon

Stephens Consulting’s Cogent Biosciences COGT Stock Holding History

Stephens Consulting’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-60
Closed -$360 – 1365
2025
Q1 		$360 Buy
+60
New +$470 ﹤0.01% 1269

Other funds holding COGT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Stephens Consulting's COGT Position: Q2 2025 in Review

Stephens Consulting sold out of Cogent Biosciences (COGT) in Q2 2025, closing a stake of 60 shares — an estimated $360 sold.

Stephens Consulting first reported a position in COGT in Q1 2025 and held it in 1 quarter. The position peaked at $360 in Q1 2025. 180 funds tracked by Wall St. Rank hold COGT as of Q2 2025.

  • Stephens Consulting reported no remaining Cogent Biosciences position as of Q2 2025 after selling out during the quarter.
  • Stephens Consulting sold 60 Cogent Biosciences shares in Q2 2025, an estimated $360.
  • Stephens Consulting first reported a position in Cogent Biosciences in Q1 2025 and held it in 1 quarter.
  • Stephens Consulting's Cogent Biosciences position peaked at $360 in Q1 2025.
  • 180 funds tracked by Wall St. Rank held Cogent Biosciences as of Q2 2025.

Based on Stephens Consulting's 13F filing for Q2 2025, filed 25 Jul 2025.